Acute Promyelocytic Leukemia - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：44頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Acute Promyelocytic Leukemia - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Acute Promyelocytic Leukemia - Pipeline Review, H1 2014’, provides an overview of the Acute Promyelocytic Leukemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Promyelocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Promyelocytic Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Promyelocytic Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Promyelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Promyelocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Promyelocytic Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Promyelocytic Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Acute Promyelocytic Leukemia - Pipeline Review, H1 2014’, provides an overview of the Acute Promyelocytic Leukemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Promyelocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Promyelocytic Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Promyelocytic Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Promyelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Promyelocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Promyelocytic Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Promyelocytic Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acute Promyelocytic Leukemia Overview 6
Therapeutics Development 7
Pipeline Products for Acute Promyelocytic Leukemia - Overview 7
Pipeline Products for Acute Promyelocytic Leukemia - Comparative Analysis 8
Acute Promyelocytic Leukemia - Therapeutics under Development by Companies 9
Acute Promyelocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 10
Acute Promyelocytic Leukemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Acute Promyelocytic Leukemia - Products under Development by Companies 14
Acute Promyelocytic Leukemia - Products under Investigation by Universities/Institutes 15
Acute Promyelocytic Leukemia - Companies Involved in Therapeutics Development 16
Teva Pharmaceutical Industries Limited 16
Toko Pharmaceutical Industries Co., Ltd. 17
Acute Promyelocytic Leukemia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
tamibarotene - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
omacetaxine mepesuccinate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Myc-Max Compounds - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
5-Hydroxy-2, 3-Indole Derivatives - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DR4 Specific Mutant TRAIL Proteins - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Combretastatin Analogues - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Acute Promyelocytic Leukemia - Recent Pipeline Updates 36
Acute Promyelocytic Leukemia - Dormant Projects 39
Acute Promyelocytic Leukemia - Product Development Milestones 40
Featured News & Press Releases 40
Aug 16, 2013: Epizyme Receives Orphan Drug Designation for EPZ-5676 40
Jul 09, 2012: CytRx Receives Notice Of Allowance Of US Patent Application For Tamibarotene Capsule 40
Apr 18, 2011: CytRx Announces Publication Of Peer-Reviewed Case Report Documenting Tamibarotene's Successful Elimination Of Recurrent Advanced-Stage Leukemia 41
Dec 07, 2009: CytRx Announces Positive Phase II Results Of Tamibarotene For The Treatment Of Relapsed Acute Promyelocytic Leukemia 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44
List of Tables
Number of Products under Development for Acute Promyelocytic Leukemia, H1 2014 7
Number of Products under Development for Acute Promyelocytic Leukemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Acute Promyelocytic Leukemia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 16
Acute Promyelocytic Leukemia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Acute Promyelocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2014 36
Acute Promyelocytic Leukemia - Dormant Projects, H1 2014 39
List of Figures
Number of Products under Development for Acute Promyelocytic Leukemia, H1 2014 7
Number of Products under Development for Acute Promyelocytic Leukemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acute Promyelocytic Leukemia Overview 6
Therapeutics Development 7
Pipeline Products for Acute Promyelocytic Leukemia - Overview 7
Pipeline Products for Acute Promyelocytic Leukemia - Comparative Analysis 8
Acute Promyelocytic Leukemia - Therapeutics under Development by Companies 9
Acute Promyelocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 10
Acute Promyelocytic Leukemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Acute Promyelocytic Leukemia - Products under Development by Companies 14
Acute Promyelocytic Leukemia - Products under Investigation by Universities/Institutes 15
Acute Promyelocytic Leukemia - Companies Involved in Therapeutics Development 16
Teva Pharmaceutical Industries Limited 16
Toko Pharmaceutical Industries Co., Ltd. 17
Acute Promyelocytic Leukemia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
tamibarotene - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
omacetaxine mepesuccinate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Myc-Max Compounds - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
5-Hydroxy-2, 3-Indole Derivatives - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DR4 Specific Mutant TRAIL Proteins - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Combretastatin Analogues - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Acute Promyelocytic Leukemia - Recent Pipeline Updates 36
Acute Promyelocytic Leukemia - Dormant Projects 39
Acute Promyelocytic Leukemia - Product Development Milestones 40
Featured News & Press Releases 40
Aug 16, 2013: Epizyme Receives Orphan Drug Designation for EPZ-5676 40
Jul 09, 2012: CytRx Receives Notice Of Allowance Of US Patent Application For Tamibarotene Capsule 40
Apr 18, 2011: CytRx Announces Publication Of Peer-Reviewed Case Report Documenting Tamibarotene's Successful Elimination Of Recurrent Advanced-Stage Leukemia 41
Dec 07, 2009: CytRx Announces Positive Phase II Results Of Tamibarotene For The Treatment Of Relapsed Acute Promyelocytic Leukemia 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44
List of Tables
Number of Products under Development for Acute Promyelocytic Leukemia, H1 2014 7
Number of Products under Development for Acute Promyelocytic Leukemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Acute Promyelocytic Leukemia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 16
Acute Promyelocytic Leukemia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Acute Promyelocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2014 36
Acute Promyelocytic Leukemia - Dormant Projects, H1 2014 39
List of Figures
Number of Products under Development for Acute Promyelocytic Leukemia, H1 2014 7
Number of Products under Development for Acute Promyelocytic Leukemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
